News
Anal Cancer
Bladder Cancer
Bone Cancer
Brain Cancer
Breast Cancer
Cancer of Unknown Primary
Cervical Cancer
Colon Cancer
Esophageal Cancer
Gastric Cancer
GIST
Head & Neck Cancer
Hodgkins Lymphoma
Leukemia
Acute Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Liver Cancer
Lung Cancer
Melanoma
Mesothelioma
Multiple Myeloma
Myelodysplastic Syndrome
MPN-PV-ET-MF
Neuroblastoma
Neuroendocrine Tumors
Non Hodgkins Lymphoma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Renal Cancer
Rectal Cancer
Sarcoma
Skin Care
Skin Cancer
Testicular Cancer
Thyroid Cancer
Triple Negative Breast Cancer
Uterine Cancer
About Us
Advertising
News
Newly Diagnosed
Treatment & Care
Survivorship
Join the Community
Newsletter
Search
Parp Inhibitors
May 7, 2022
Understanding Your Breast Pathology Report
Charles H. Weaver, MD
March 4, 2021
Update on PARP Inhibitors & Other Precision Cancer Medicines for Ovarian Cancer
Charles H. Weaver, MD
January 23, 2021
Precision Cancer Medicines for Prostate Cancer
Charles H. Weaver, MD
November 26, 2020
Treatment of Stage IV – Metastatic Pancreatic Cancer
Charles H. Weaver, MD
November 16, 2020
Precision Cancer Medicines for Ovarian Cancer
Charles H. Weaver, MD
November 7, 2020
PARP Inhibitors Shows Promise as Treatment for Pancreatic Cancer
Charles H. Weaver, MD
September 30, 2020
PARP Inhibitors – Effective in Men with BRCA-Mutant Prostate Cancer
Charles H. Weaver, MD
September 23, 2020
Lynparza Delays Progression & Significantly Prolongs Survival in Ovarian Cancer
Charles H. Weaver, MD
August 22, 2020
Treatment & Management of Ovarian Cancer
Charles H. Weaver, MD
August 18, 2020
Treatment of Early Stage TNBC
Charles H. Weaver, MD
June 5, 2020
Treatment of Recurrent Ovarian Cancer
Charles H. Weaver, MD
October 2, 2019
Zejula (Niraparib) Improves Progression-Free Survival in Ovarian Cancer
Charles H. Weaver, MD
1
2
Next Page
Loading Comments...
Write a Comment...
Email (Required)
Name (Required)
Website
